相关实验视频

Updated: Jul 16, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

预测Trifluridine/Tipiracil治疗结果在耐火转移性结肠直肠癌患者:一个多中心的探索性分析

Juraj Prejac^1,2, Tomislav Omrčen^3,4, Jasna Radić^5,6

¹Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia.

|September 12, 2023

概括

三里丁/提皮拉西尔 (TTP) 在耐火性转移性结直肠癌 (mCRC) 中显示出潜力. 沉默性疾病,良好的表现状况和没有肝转移预测了接受TTP的患者的更好的结果.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
药理学药理学是指药理学的学科.

背景情况:

没有确立的生物标志物用于识别转移性结直肠癌 (mCRC) 患者,这些患者最受益于trifluridine/tipiracil (TTP).
以前的试验表明,患有较低瘤负担和惰性疾病的患者可能从TTP中获得更多的益处.
现实世界的数据对于理解TTP在晚期mCRC中的影响至关重要.

研究的目的:

调查TTP在mCRC中的有效性.
确定影响耐火性疾病患者TTP治疗结果的因素.

主要方法:

在2018-2020年期间,对260名在第三或第四线接受TTP治疗的患者进行了回顾性分析.
包括来自克罗地亚三个主要瘤中心的数据.
与疾病特征相关的无进展生存 (PFS) 和总生存 (OS) 的评估.

主要成果:

平均生存期为6.53个月,平均PFS为2.50个月.
患有更具侵略性的疾病 (进展时间<18个月) 的患者的PFS显著缩短.
较长的生存期和PFS的积极预测因素包括ECOG PS 0,缺少肝转移和RAS突变.

结论:

沉默性疾病,良好的整体状况 (ECOG PS 0) 和缺少肝转移是mCRC中TTP治疗的积极预测因素.
这些因素与之前的试验结果和现实世界的观察结果一致.
对于一些耐火性mCRC的患者来说,TTP仍然是一个有价值的选择.

关键词:

探索性分析是一种探索性分析.转移性结直肠癌是什么意思患者的选择患者的选择预测因素是指预测因素.三里丁/蒂皮拉西尔

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...